Extracellular Acidosis Differentially Regulates Estrogen Receptor β-Dependent EMT Reprogramming in Female and Male Melanoma Cells

Int J Mol Sci. 2022 Dec 6;23(23):15374. doi: 10.3390/ijms232315374.

Abstract

Clinical outcomes of melanoma patients pointed out a gender disparity that supports a correlation between sex hormone activity on estrogen receptors (ER) and melanoma development and progression. Here, we found that the epithelial-to-mesenchymal transition (EMT) of melanoma cells induced by extracellular acidosis, which is a crucial hallmark of solid cancers, correlates with the expression of ERβ, the most representative ER on melanoma cells. Extracellular acidosis induces an enhanced expression of ERβ in female cells and EMT markers remain unchanged, while extracellular acidosis did not induce the expression of ERβ in male cells and EMT was strongly promoted. An inverse relationship between ERβ expression and EMT markers in melanoma cells of different sex exposed to extracellular acidosis was revealed by two different technical approaches: florescence-activated cell sorting of high ERβ expressing cell subpopulations and ERβ receptor silencing. Finally, we found that ERβ regulates EMT through NF-κB activation. These results demonstrate that extracellular acidosis drives a differential ERβ regulation in male and female melanoma cells and that this gender disparity might open new perspectives for personalized therapeutic approaches.

Keywords: NF-κB; epithelial-to-mesenchymal transition; estrogen receptor β; extracellular acidity; human melanoma.

MeSH terms

  • Cell Line, Tumor
  • Epithelial-Mesenchymal Transition / genetics
  • Estrogen Receptor alpha
  • Estrogen Receptor beta* / genetics
  • Estrogen Receptor beta* / metabolism
  • Female
  • Humans
  • Male
  • Melanoma* / genetics
  • Melanoma* / metabolism
  • Receptors, Estrogen / metabolism

Substances

  • Estrogen Receptor beta
  • Receptors, Estrogen
  • Estrogen Receptor alpha

Grants and funding

This research was funded by Progetto di Ateneo Università di Firenze; S.P. was supported by Accademia Nazionale dei Lincei and by the Ministry of Education, Universities, and Research of Italy (Progetto Dipartimenti di Eccellenza ‘Gender Medicine’); E.A. and A.B. were supported by a post-doctoral fellowship of the Fondazione Italiana per la Ricerca sul Cancro (FIRC).